Abstract
The tumor microenvironment is dynamically regulated by complex post-translational modifications (PTMs), which play pivotal roles in cancer immunity. Ubiquitination, along with other PTMs such as phosphorylation, glycosylation, and acetylation, orchestrates immune checkpoint activity and immune cell function, shaping antitumor responses. In this review, we discuss the intricate crosstalk and regulatory mechanisms between ubiquitination and other PTMs in cancer immunity. Studies have revealed that the stability and function of immune checkpoint proteins, such as PD-L1, are dynamically regulated by synergistic or competitive modifications, which directly shape the tumor microenvironment’s immunological characteristics. We highlight how PTMs regulate immune cell function (e.g., T cells, NK cells, and macrophages) and key signaling pathways (e.g., STAT, type I IFN, and NF-κB) in the TME. Furthermore, we summarize potential therapeutic strategies targeting these PTMs, including small-molecule inhibitors and novel technologies (e.g., PROTACs and cell-penetrating peptides), which offer insights into overcoming immunotherapy resistance and optimizing combination therapies. Future research should explore non-classical PTMs and leverage multi-omics approaches to refine precision immunotherapy strategies.
Similar content being viewed by others
Acknowledgements
Figures were created with BioRender software (https://biorender.com). We thank International Science Editing (http://www.internationalscienceediting.com) for editing this manuscript. No funding was received for this research.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Consent for publication
All authors have agreed to publish this manuscript.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Li, KQ., Ding, SQ., Lei, Y. et al. Decoding the crosstalk between ubiquitination and other post-translational modifications in cancer immunity: from mechanisms to clinical prospects. npj Precis. Onc. (2026). https://doi.org/10.1038/s41698-026-01488-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41698-026-01488-w
